🇺🇸 FDA
Pipeline program

ENMD-2076

2076-CL-004

Phase 2 small_molecule completed

Quick answer

ENMD-2076 for Ovarian Cancer is a Phase 2 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
CASI Pharmaceuticals
Indication
Ovarian Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials